

Correction

Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG₁ Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies

In this article (Clin Cancer Res 2010;16:1915–27), which was published in the March 15, 2010 issue of *Clinical Cancer Research* (1), Table 3 was incorrectly formatted. The correct table appears below:

Table 3. Adverse events related to necitumumab

Adverse event*	Arm A (n = 29)			Arm B (n = 31)		
	All grades	Study day	Grade $\geq 3^{\dagger}$	All grades	Study day	Grade $\geq 3^{\dagger}$
Acne	16 (55.2%)	152	1 (3.4%)	10 (32.3%)	26	1 (3.2%)
Acneform dermatitis	3 (10.3%)		0	11 (35.5%)		0
Anemia	1 (3.4%)		0	3 (9.7%)	50	1 (3.2%)
Blood magnesium decreased	1 (3.4%)		0	1 (3.2%)	101	1 (3.2%)
Diarrhea	1 (3.4%)		0	1 (3.2%)	11	1 (3.2%)
Dry skin	12 (41.4%)		0	6 (19.4%)		0
Fatigue	7 (24.1%)	36, 43	2 (6.9%)	9 (29.0%)	23, 70	2 (6.5%)
Headache	10 (34.5%)		0	15 (48.4%)	1, 1	2 (6.5%)
Hypokalemia	0		0	1 (3.2%)	56	1 (3.2%)
Nausea	9 (31.0%)		0	11 (35.5%)	2	1 (3.2%)
Pruritus	3 (10.3%)		0	7 (22.6%)		0
Pyrexia	6 (20.7%)		0	13 (41.9%)		0
Skin fissures	10 (34.5%)		0	3 (9.7%)		0
Vomiting	6 (20.7%)		0	6 (19.4%)	2	1 (3.2%)

*Most common and most severe adverse events (all events of worst grade ≥ 3 or affecting at least 20% of patients in either arm).

[†]Worst grade per patient.

Also, on page 1,922, the last sentence should read, "For example, in patients treated with necitumumab 800 mg every 2 weeks, trough concentrations (14 days posttreatment and immediately prior to the next treatment) averaged 83 $\mu\text{g}/\text{mL}$ after the final dose of cycle 1," not "between 78 and 83 $\mu\text{g}/\text{mL}$, respectively, after the first and final dose of cycle 1."

Reference

1. Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG₁ monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16:1915–27.

Published OnlineFirst 09/07/2010.

©2010 American Association for Cancer Research.

doi: 10.1158/1078-0432.CCR-10-2072

Clinical Cancer Research

Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG₁ Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies

Clin Cancer Res 2010;16:4681. Published OnlineFirst September 7, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-10-2072](https://doi.org/10.1158/1078-0432.CCR-10-2072)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/16/18/4681.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/18/4681>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.